These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1588152)

  • 1. Further approaches for optimizing polysaccharide-protein conjugate vaccines for prevention of invasive bacterial disease.
    Jennings H
    J Infect Dis; 1992 Jun; 165 Suppl 1():S156-9. PubMed ID: 1588152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines.
    de Velasco EA; Merkus D; Anderton S; Verheul AF; Lizzio EF; Van der Zee R; Van Eden W; Hoffman T; Verhoef J; Snippe H
    Infect Immun; 1995 Mar; 63(3):961-8. PubMed ID: 7532630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic considerations for the development of conjugate vaccines.
    Garner CV; Pier GB
    Contrib Microbiol Immunol; 1989; 10():11-7. PubMed ID: 2510971
    [No Abstract]   [Full Text] [Related]  

  • 4. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

  • 5. Preparation, antigenicity, and immunogenicity of synthetic ribosylribitol phosphate oligomer-protein conjugates and their potential use for vaccination against Haemophilus influenzae type b disease.
    Evenberg D; Hoogerhout P; van Boeckel CA; Rijkers GT; Beuvery EC; van Boom JH; Poolman JT
    J Infect Dis; 1992 Jun; 165 Suppl 1():S152-5. PubMed ID: 1588151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in synthetic oligosaccharide-based bacterial vaccines.
    Pozsgay V
    Curr Top Med Chem; 2008; 8(2):126-40. PubMed ID: 18289082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.
    Madoff LC; Paoletti LC; Tai JY; Kasper DL
    J Clin Invest; 1994 Jul; 94(1):286-92. PubMed ID: 7518832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cellular basis of the immune response to conjugate vaccines.
    Bixler GS; Pillai S
    Contrib Microbiol Immunol; 1989; 10():18-47. PubMed ID: 2684506
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.
    Paoletti LC; Kasper DL; Michon F; DiFabio J; Jennings HJ; Tosteson TD; Wessels MR
    J Clin Invest; 1992 Jan; 89(1):203-9. PubMed ID: 1729272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Streptococcus pneumoniae type 14 polysaccharide-conjugate vaccines: length stabilization of opsonophagocytic conformational polysaccharide epitopes.
    Laferriere CA; Sood RK; de Muys JM; Michon F; Jennings HJ
    Infect Immun; 1998 Jun; 66(6):2441-6. PubMed ID: 9596700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemically modified capsular polysaccharides as vaccines.
    Jennings HJ
    Adv Exp Med Biol; 1988; 228():495-550. PubMed ID: 2459932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic carbohydrate-based vaccines: challenges and opportunities.
    Mettu R; Chen CY; Wu CY
    J Biomed Sci; 2020 Jan; 27(1):9. PubMed ID: 31900143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immune responses to polysaccharide antigens: an analysis of bacterial polysaccharide vaccines in infants.
    Barrett DJ
    Adv Pediatr; 1985; 32():139-58. PubMed ID: 3909772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharide or conjugate vaccine after primary immunization with conjugate vaccines.
    Käyhty H; Eskola J; Peltola H; Saarinen L; Mäkelä PH
    J Infect Dis; 1992 Jun; 165 Suppl 1():S165-6. PubMed ID: 1588156
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine.
    Donnelly JJ; Deck RR; Liu MA
    J Immunol; 1990 Nov; 145(9):3071-9. PubMed ID: 2120344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response of young children vaccinated with Haemophilus influenzae type b conjugate vaccines.
    Madore DV; Phipps DC; Eby R; Johnson CL; Smith DH
    Contrib Microbiol Immunol; 1989; 10():125-50. PubMed ID: 2684505
    [No Abstract]   [Full Text] [Related]  

  • 17. [Methodological approaches to designing chemical vaccines against bacterial infections].
    Kostiukova NN; Ezepchuk IuV
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Aug; (8):3-8. PubMed ID: 6207689
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential regulation of polysaccharide-specific antibody responses to isolated polysaccharides, conjugate vaccines, and intact Gram-positive versus Gram-negative extracellular bacteria.
    Snapper CM
    Vaccine; 2016 Jun; 34(30):3542-8. PubMed ID: 27133879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197.
    Anderson PW; Pichichero ME; Stein EC; Porcelli S; Betts RF; Connuck DM; Korones D; Insel RA; Zahradnik JM; Eby R
    J Immunol; 1989 Apr; 142(7):2464-8. PubMed ID: 2784464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of invasive bacterial diseases by immunization with polysaccharide-protein conjugates.
    Robbins JB; Schneerson R; Szu SC; Fattom A; Yang Y; Lagergard T; Chu C; Sørensen US
    Curr Top Microbiol Immunol; 1989; 146():169-80. PubMed ID: 2659266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.